Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil

Liver Transplantation

Volumn 13, Issue 6, 2007, Pages 791-796

  Jain, Ashokkumar ^a,b   Venkataramanan, Raman ^b   Kwong, Tai ^a   Mohanka, Ravi ^a   Orloff, Mark ^a   Abt, Peter ^a   Kashyap, Randeep ^a   Tsoulfas, Georgios ^a   Mack, Cindy ^a   Williamson, Mary ^a   Batzold, Pam ^a   Bozorgzadeh, Adel ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CADAVER DONOR; CLINICAL ARTICLE; COMPUTER PROGRAM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; LIVER TRANSPLANTATION; MALE; MAXIMUM PLASMA CONCENTRATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES;

EID: 34250613511     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21146     Document Type: Article

References (49)

1. Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991;23(2 Suppl 2):10-14.
2. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation 1992;53:428-432.
3. Jain A, Khanna A, Molmenti EP, Rishi N, Fung JJ. Immunosuppressive therapy. Surg Clin North Am 1999;79:59-76.
4. Danovitch GM. Mycophenolate mofetil in renal transplantation: results from the U.S. randomized trials. Kidney Int Suppl 1995;52:S93-96.
5. Behrend M. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Clin Nephrol 1996;45:336-341.
6. Halloran P, Mathew T, Toanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997;63:39-47.
7. Klupp J, Bechstein WO, Platz KP, Keck, H, Lemmens, HP, Knoop, M. et al. Mycophenolate mofetil added to immunosuppression after liver transplantation-first results. Transpl Int 1997;10:223-228.
8. Eckhoff DE, McGuire BM, Frenette LP, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998;65:180-187.
9. Fisher RA, Stone JJ, Wolfe LG, et al. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation. Clin Transplant 2004;18:462-472.
10. Jain A, Kashyap R, Dodson F, Kramer, D Hamad, I Khan, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 2001;72:1091-1097.
11. Jain A, Mohanka R, Orloff M, Abt P, Kashyap R, Kelley M, et al. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation. Exp Clin Transplant 2005;3:361-364.
12. Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer, R, Schroder, H, et al. Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. Ther Drug Monit 2005;27: 315-321.
13. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-324.
14. Ensom MH, Partovi N, Decarie D, Ignaszewski AP, Fradet GJ, Levy RD. Mycophenolate pharmacokinetics in early period following lung or heart transplantation. Ann Pharmacother 2003;37:1761-1767.
15. Jain A, Venkataramanan R, Hamad IS, Zuckerman, S, Zhang, S, Lever, J, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001;41:268-276.
16. Pisupati J, Jain A, Burckart G, Hamad, I, Zuckerman, S, Fung, J, et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005;45:34-41.
17. Jain A, Mohanka R, Kwong T, Mack, C, Nelson, J, Orloff, M, et al. Kinetics of IV mycophenolate mofetil (MMF) and oral MMF in live donor and deceased donor liver transplantation (LTx). Hepatology 2005;42(Suppl 1):329A (Abstract 338).
18. Shipkova M, Niedmann PD, Armstrong VW, Schutz, E, Wieland, E, Shaw, LM, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998;44:1481-1488.
19. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Transplantation 1996;61:722-729.
20. Rescue therapy with mycophenolate mofetil. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Clin Transplant 1996;10:131-135.
21. Aleksic I, Baryalei M, Busch T, Pieske, B, Schorn, B, Strauch, J, et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000; 69:1586-1590.
22. Barten MJ, van Gelder T, Gummert JF, Boeke K, Shorthouse R, Billingham ME, Morris RE, et al. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am J Transplant 2002;2:719-732.
23. Dipchand AI, Pietra B, McCrindle BW, Rosebrook-Bicknell HL, Boucek MM. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant 2001;20:1035-1043.
24. Mathieu P, Carrier M, White M, Pellerin M, Perrault L, Pelletier G, et al. Effect of mycophenolate mofetil in heart transplantation. Can J Surg 2000;43:202-206.
25. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004;18:485-492.
26. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-232.
27. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61:1029-1037.
28. Lafferty ME, Lang S, McGregor E, Henderson IS, Jones MC. Treatment of severe acute vascular rejection in a renal allograft with mycophenolate mofetil and high dose steroids. Scott Med J 1997;42:79-80.
29. Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 1999;31:1113-1114.
30. Hebrt MF CT, Linna TJ, Roberts JP. Pharmacokinetics of intravenous mycophenolate mofetil in liver transplant patients [Abstract]. Clin Pharmacol Ther 1996;59:184.
31. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-455.
32. Brunet M, Cirera I, Martorell J, Vidal E, Millan O, Jimenez O, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006;81:541-546.
33. Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 1999;66:492-500.
34. Johnson HJ, Swan SK, Heim-Duthoy KL, Nicholls AJ, Tsina I, Tarnowski T. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther 1998; 63:512-518.
35. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003;3:534-542.
36. Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998;38:268-275.
37. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997;5:225-235.
38. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28:925-929.
39. Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico, N, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001;15:402-409.
40. Gonzalez-Roncero FM, Gentil MA, Brunet M, Algarra G, Pereira P, Cabello V, Peralvo M, et al. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc 2005;37:3749-3751.
41. Brusa P, Ceruti M, Casullo R, Dosio F, Squiccimarro G, Segoloni GP, Cattel L, et al. Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients. Farmaco 2000;55:270-275.
42. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 1999;21:498.
43. Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y, et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003;43:866-880.
44. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000;22:14-19.
45. Atcheson BA, Taylor PJ, Kirkpatrick CM, Duffull SB, Mudge DW, Pillans PI, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 2004;26:284-286.
46. Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients. Int J Clin Pharmacol Ther 2005;43:379-388.
47. Pescovitz MD, Conti D, Dunn J, Gonwa T, Halloran P, Sollinger H, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 2000;14:179-188.
48. Hale MD, Nicholls AJ, Bullingham RE, Hene R, Hoitsma A, Squifflet JP, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-683.
49. Mourad M, Malaise J, Chaib Eddour D, De Meyer M, Konig J, Schepers R, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001;47:1241-1248.